Source link : https://www.newshealth.biz/health-news/is-doac-a-viable-option-after-bioprosthetic-valve-surgery-even-in-sinus-rhythm/
CHICAGO — Edoxaban (Savaysa) appeared at least on par with warfarin for 12-week thromboembolic prophylaxis after bioprosthetic valve surgical implant in a Japanese trial with a population largely in sinus rhythm, but small numbers made the results inconclusive. Edoxaban had a numerically lower rate of the primary outcome of stroke or systemic embolism at 0.5% […]
Author : News Health
Publish date : 2024-11-17 22:34:12
Copyright for syndicated content belongs to the linked Source.